PrEP is one of the clearest wins in modern sexual health, and demand for private, discreet access sits alongside NHS provision that some patients find slow to reach or would rather avoid for privacy reasons. A telehealth PrEP service can genuinely extend access — but only if it is built around the testing regime that makes PrEP safe, not just the prescription that makes it convenient.
Why PrEP suits telehealth — with conditions
Pre-exposure prophylaxis is a well-defined, guideline-driven intervention: a person not living with HIV takes tenofovir disoproxil/emtricitabine (branded as Truvada, or a generic equivalent) to substantially reduce the risk of acquiring HIV through sex. That clarity, plus real demand from people who want faster or more private access than their local sexual health clinic can offer, makes it a plausible telehealth vertical.
The condition is that PrEP is not a one-off prescription — it is an ongoing clinical relationship built on testing. A service that treats it as a simple repeat-prescription product, without the monitoring infrastructure behind it, is not offering PrEP safely. It is offering an antiretroviral with the safety net removed.
The NHS comparison: what private telehealth adds
PrEP has been available free through NHS sexual health (GUM) services in England since 2020, following NICE-informed commissioning, with similar routes in Scotland, Wales and Northern Ireland. Any private or telehealth PrEP service exists alongside that, not instead of it, and should say so plainly rather than implying PrEP is otherwise unavailable.
What private telehealth typically adds is speed of access, appointment flexibility and privacy for people who would rather not attend a local clinic — not a clinically different product. Being upfront about the free NHS route, including in marketing copy, keeps a service credible and avoids the appearance of gatekeeping something that already exists at no cost.
Baseline and ongoing monitoring
This is the section that makes or breaks a PrEP service. Before starting, guidance from bodies such as BHIVA and BASHH points to a baseline HIV test, renal function check (eGFR), and hepatitis B status — because stopping PrEP in a patient with undiagnosed chronic hepatitis B can trigger a serious flare, so HBV status has to be known, not assumed.
- Baseline HIV test — PrEP must not be started during undiagnosed acute HIV infection; starting it then risks masking infection and driving resistance.
- Renal function — tenofovir affects the kidneys, so eGFR needs checking before starting and periodically thereafter.
- Hepatitis B status — determines both safe use and what happens if the patient stops.
- Ongoing STI and HIV testing — regular retesting while on PrEP, per current clinical guidance, is not optional paperwork; it is the mechanism that catches a breakthrough infection early.
A remote service that skips or waves through this testing to speed up the funnel has built a supply chain for an antiretroviral, not a clinical service.
PrEP is not a repeat-prescription product wearing a sexual-health label. Baseline HIV, renal and hepatitis B testing, plus a real ongoing retesting cadence, are what make remote PrEP safe — skip them and you are dispensing an antiretroviral without the safety net that justifies doing it remotely at all.
Dosing models and prescriber judgement
Daily oral dosing is the standard PrEP regimen. Some services also discuss event-based ("on-demand") dosing for people having planned, less frequent sex, following BHIVA/BASHH guidance — but the choice between regimens is a clinical judgement made with the prescriber based on the individual's pattern of risk and ability to plan around sex, not a menu option a patient self-selects at checkout. Prescriber discretion applies throughout.
Adherence is the other variable that determines whether PrEP actually protects. A telehealth service should build in adherence support — clear counselling at the point of prescribing and structured check-ins — rather than treating the sale as the end of the relationship.
Who falls outside remote PrEP
Scope discipline matters as much here as in any other remote-prescribing vertical. Someone with symptoms suggestive of acute HIV seroconversion illness needs urgent same-day testing and assessment, not a routine remote consultation and a script. Significant renal impairment, unclear hepatitis B status that can't be resolved before prescribing, and uncertainty about ongoing testing engagement are all reasons to slow down or decline rather than proceed.
The same identity and appropriateness discipline that applies to other restricted-medicine pathways applies here — see our guide to verification for restricted medicines. PrEP sits in the same category as other services covered in our sexual health and STI telehealth guide: genuine demand, real regulatory weight, no shortcuts on triage.
A PrEP service that treats the prescription as the product, and testing as an afterthought, has built a supply chain for an antiretroviral — not a clinical service.
Building the testing and dispensing loop
Operationally, PrEP is less about the prescription and more about the loop around it: baseline testing (postal kits or partnered phlebotomy), a prescriber review that actually reads the results before dispensing, dispensing and delivery of the medicine itself, and a recall system that reliably brings patients back for their next round of monitoring rather than hoping they remember.
Postal or in-clinic blood testing is worth building deliberately rather than bolting on — see our guide on adding a private blood testing service. Underneath all of it sits the same regulated spine as any other prescribing vertical: registered dispensing, prescriber governance and a patient record that ties testing history to prescribing decisions. Our launch checklist covers the sequence for standing this up.
How PExpo supports a PrEP launch
PExpo provides the regulated layer behind a PrEP service — registered dispensing, prescriber governance, pharmacovigilance and a patient record built to hold testing history alongside prescribing — so a brand can launch on a compliant base rather than assembling one from scratch.
You bring the brand, the funnel and the patient experience; the testing discipline and prescribing governance run on infrastructure built for exactly this kind of ongoing, monitoring-dependent service. See our brand model and pricing.
PrEP rewards operators who build the testing loop first and the prescribing funnel second: baseline HIV, renal and hepatitis B checks, a genuine ongoing retesting cadence, and honesty about the free NHS route sitting alongside a private one. See our sexual health telehealth guide and launch checklist for the wider operational detail.
Frequently asked questions
Can you get PrEP through a UK telehealth service?
Yes — private telehealth services can prescribe PrEP (tenofovir disoproxil/emtricitabine) to eligible adults, sitting alongside free NHS PrEP available through sexual health clinics. A safe remote service requires baseline HIV, renal function and hepatitis B testing before prescribing, plus ongoing monitoring. Prescriber discretion applies.
Is PrEP free on the NHS in the UK?
Yes, PrEP has been commissioned through NHS sexual health services since 2020 in England, with similar routes elsewhere in the UK. Private telehealth PrEP services exist for people who want faster access, more flexible appointments, or added privacy — not because PrEP is otherwise unavailable, and reputable services say so clearly.
What testing does PrEP require?
Guidance from bodies such as BHIVA and BASHH points to a baseline HIV test, renal function check, and hepatitis B status before starting, plus ongoing HIV and STI retesting at intervals while on PrEP. This monitoring is what makes ongoing PrEP use safe, not a one-off formality.
